|Venture Fund Member Profile
At Polaris we provide more than capital. We add value to the companies in which we invest by actively partnering with each entrepreneur and management team to help propel their ideas into market leading businesses.
As part of the support we provide our portfolio companies, we recruit and attract employees at all levels. We identify and structure strategic partnerships. We raise additional equity and debt financing. And, we're available 24/7 to help solve problems, identify opportunities, and detect "land mines." At the same time, we know the difference between being a coach and a player. We respect the individuality and inspiration that drive the entrepreneurs in whom we invest.
We also take a long-term view of our partnerships. We know that building a successful company takes time. In partnering for the life cycle of companies, we provide access to Polaris' expertise and network at all stages of a company's development and across all strategic areas of the business.
Polaris Venture Partners
Kevin J. Bitterman is a principal in our Boston office. Kevin joined Polaris in July 2004 and focuses on investments in the life sciences.
Prior to joining Polaris, Kevin completed his Ph.D. in genetics at Harvard Medical School under the guidance of Dr. David Sinclair. His doctoral research focused on small molecule regulation of a novel class of protein deacetylases. Kevin has authored papers in the journals Nature, Science and Molecular Cell and is a cofounder of Sirtris Pharmaceuticals.
Kevin currently represents Polaris as a Director of Biolex Therapeutics, Certus Biomedical, Follica Inc., Genocea Biosciences, Parasol Therapeutics and Solace Pharmaceuticals. Additionally, Kevin is a Board Observer to Pulmatrix Inc. and Tempo Pharmaceuticals.
Prior to obtaining his Ph.D. at Harvard Medical School, Kevin earned a B.A. with Highest Honors from Rutgers College with a major in Biological Sciences and a minor in Philosophy.
||Cerulean Pharma is developing a proprietary nanoparticle technology designed to improve the safety and efficacy of marketed and development-stage drugs. Tempo intends to build a deep pipeline of drug products utilizing its core technology. The Company was founded by Polaris. |
||TechTarget offers the most targeted media for enterprise IT professionals, including invitation-only conferences, e-mail newsletters, Webcasts, Storage magazine, and the only network IT Web sites targeted to specific segments of the IT market. TechTarget’s more than 1500 advertisers include the world’s leading IT companies.|
||Pulmatrix is developing safe and effective inhaled therapeutics that utilize the inherent properties of the airway to treat, prevent, and control the spread of respiratory infectious disease.|
||170 Systems develops best-of-breed financial process applications that are the foundation for world-class finance operations in Global 2000 organizations. Designed to complement the ERP’s transactional core, its products automate end-to-end financial processes with consistent best practices and leverage the latest capture technologies (imaging, OCR, e-Invoicing and others) to reduce operational costs and improve speed, visibility, quality, and enforcement of internal controls.|
Kevin participated in the FundingPost event: Boston Early-Stage Angel and Venture Event
on Wednesday, June 24, 2009 in MA, Sponsored by Bingham McCutchen LLP
To list your Company on our website and make your profile available to Kevin and 7,500+ other VCs and Angel Investors, Click Here.
For over Twelve Years FundingPost has worked with thousands
of Angel and Venture Capital Investors. We believe that it is
important to reach investors in every medium possible -
both online and offline. We have been directly responsible for
tons of success stories and Millions and Millions of dollars raised.
We look forward to introducing your company to the leading Venture and Angel Investors nationwide.
|Venture Fund Member Profile|